Charles River SITC/EORTC 2019 Poster Presentations

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 26-30, 2019 | Boston, MA

The Society for Immunotherapy of Cancer's 34th Annual Meeting
November 6-10, 2019 | National Harbor, MD

Abstract 3D render of of virus cells. Shallow depth of field.

Charles River Poster Presentations

Charles River experts presented the following posters at the International Conference on Molecular Targets and Cancer Therapeutics and Society for Immunotherapy of Cancer's 34th Annual Meeting. Below, you can download any of our poster presentations covering a variety of research topics.

A kinetic analysis of tumor gene expression and cellular changes following immune checkpoint inhibition in the MC38 colon carcinoma model | Patrick Fadden

A translational platform to assess immuno-modulation of the tumor microenvironment | Louise Brackenbury

Building a translational pathway using pharmacodynamic and syngeneic tumor models in conjunction with gene expression to enable the development of cancer immune therapies | Louise Brackenbury

Characterization of a panel of 79 PDX-derived cell lines with a focus on the EGFR exon 20 insertion mutation-driven NSCLC model LXFE 2478 | Thomas Metz

CRISPR CAS9 mediated BRCA1 knockout modulates the tumor infiltrating lymphocytes landscape and cytokine profile in a murine breast cancer model | Julia Schüler

Laminar Wash™ AUTO system: a reliable walk-away sample preparation solution for better TILs recovery without centrifugation | Ira Kim

NCG/CRL as a novel (Charles River) humanized mouse model for preclinical oncology studies: immunophenotypic characterization and performance monitoring | Christoph Eberle and Jenny Rowe

Novel in vivo preclinical humanized models for the evaluation of human specific immune checkpoint inhibitors | Paula Miliani de Marval

The percentage of tumor infiltrating lymphocytes in a panel of solid cancer PDX models correlates with a specific human cytokine pattern in peripheral blood of the tumor bearing animal | Julia Schueler

Validation of the interaction between a candidate compound and the intended drug target by a phenotypic rescue approach | Ian Waddell

Explore Some of Our Capabilities

Cancer drug discovery has advanced significantly in the last decade. The tool kits of drug discovery scientists are becoming increasingly more sophisticated and translational. Charles River is dedicated to guiding oncology researchers, leveraging our unmatched portfolio of in vitro and in vivo models and expertise in immunology, by providing a comprehensive offering of translational oncology discovery services.